Kura Oncology (KURA) Cut to Sell at BidaskClub

BidaskClub cut shares of Kura Oncology (NASDAQ:KURA) from a hold rating to a sell rating in a research report released on Tuesday.

Other equities analysts have also issued reports about the stock. Oppenheimer set a $18.00 price objective on shares of Kura Oncology and gave the company a buy rating in a research report on Monday, December 11th. Cann reiterated a buy rating and issued a $17.50 price objective on shares of Kura Oncology in a research report on Monday, December 11th. Wedbush initiated coverage on shares of Kura Oncology in a research report on Tuesday, December 26th. They issued a buy rating and a $19.00 price objective on the stock. Zacks Investment Research upgraded shares of Kura Oncology from a hold rating to a buy rating and set a $15.00 price objective on the stock in a research report on Friday, September 15th. Finally, Citigroup lifted their price objective on shares of Kura Oncology from $15.00 to $19.00 and gave the company a buy rating in a research report on Thursday, November 9th. Three analysts have rated the stock with a sell rating and six have given a buy rating to the company’s stock. The stock currently has a consensus rating of Hold and an average target price of $18.08.

Kura Oncology (NASDAQ:KURA) traded up $0.40 during trading hours on Tuesday, reaching $16.05. 133,729 shares of the company were exchanged, compared to its average volume of 179,598. Kura Oncology has a 1 year low of $5.78 and a 1 year high of $17.50. The company has a current ratio of 13.48, a quick ratio of 13.48 and a debt-to-equity ratio of 0.07. The stock has a market cap of $472.87, a price-to-earnings ratio of -10.35 and a beta of 4.89.

Kura Oncology (NASDAQ:KURA) last posted its quarterly earnings data on Tuesday, November 7th. The company reported ($0.38) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.01). equities research analysts anticipate that Kura Oncology will post -1.52 earnings per share for the current year.

Several hedge funds and other institutional investors have recently modified their holdings of the business. California State Teachers Retirement System boosted its position in shares of Kura Oncology by 24.5% during the 3rd quarter. California State Teachers Retirement System now owns 31,500 shares of the company’s stock worth $471,000 after purchasing an additional 6,200 shares in the last quarter. Nationwide Fund Advisors boosted its position in shares of Kura Oncology by 66.2% during the 2nd quarter. Nationwide Fund Advisors now owns 25,758 shares of the company’s stock worth $240,000 after purchasing an additional 10,258 shares in the last quarter. State of Wisconsin Investment Board purchased a new stake in shares of Kura Oncology during the 2nd quarter worth $102,000. Rhumbline Advisers purchased a new stake in shares of Kura Oncology during the 2nd quarter worth $131,000. Finally, Schwab Charles Investment Management Inc. boosted its position in shares of Kura Oncology by 61.3% during the 3rd quarter. Schwab Charles Investment Management Inc. now owns 39,200 shares of the company’s stock worth $587,000 after purchasing an additional 14,900 shares in the last quarter. Institutional investors own 64.26% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Kura Oncology (KURA) Cut to Sell at BidaskClub” was published by Stock Observer and is the sole property of of Stock Observer. If you are viewing this story on another domain, it was copied illegally and republished in violation of United States and international copyright laws. The legal version of this story can be viewed at https://www.thestockobserver.com/2018/01/13/kura-oncology-kura-cut-to-sell-at-bidaskclub.html.

About Kura Oncology

Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.

Analyst Recommendations for Kura Oncology (NASDAQ:KURA)

Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply